Literature DB >> 15325079

Fiber-mosaic adenovirus as a novel approach to design genetically modified adenoviral vectors.

Larisa Pereboeva1, Svetlana Komarova, Parameshwar J Mahasreshti, David T Curiel.   

Abstract

Genetic modification of the adenovirus (Ad) capsid is one of the successful strategies to achieve viral retargeting. However, it has been widely recognized that structural constraints imposed by viral proteins limit the number and nature of incorporated targeting ligands and often hamper viral propagation. To address this issue, we propose a genetic fiber-mosaic virus (having two distinct fibers in one viral particle) as a means to facilitate fiber modifications. Fiber-mosaic virus having tandem fibers: a wild type (wt) fiber and second adjunctive fiber, will utilize natural viral entry for the conventional propagation of the vectors whereas, adjunctive fiber will serve multiple potential purposes such as targeting, purification, or imaging of viral particles via genetic incorporation of the corresponding functional moieties. We generated the mosaic adenovirus vector encoding two fibers: wild-type and adjunctive fiber--Fiber-Fibritin (FF) and confirmed incorporation of FF in the mosaic viral particles. We investigated binding specificity of the mosaic virus and the possible interference of the two fibers during virus life cycle. Fiber-mosaic Ad attained new binding properties provided by the second fiber, while preserving the binding ability attributed to the wt fiber. Our results suggest that the two fibers being presented and structurally separated on the viral particle may also function separately as binding counterparts for virus attachment. Therefore, the mosaic setting will allow more flexibility in Ad retargeting approaches.

Mesh:

Substances:

Year:  2004        PMID: 15325079     DOI: 10.1016/j.virusres.2004.04.012

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  7 in total

Review 1.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

2.  Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.

Authors:  L Pereboeva; S Komarova; J Roth; S Ponnazhagan; D T Curiel
Journal:  Gene Ther       Date:  2007-01-25       Impact factor: 5.250

Review 3.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

4.  A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway.

Authors:  Yuko Tsuruta; Larisa Pereboeva; Joel N Glasgow; Daniel T Rein; Yosuke Kawakami; Ronald D Alvarez; Rodney P Rocconi; Gene P Siegal; Paul Dent; Paul B Fisher; David T Curiel
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

5.  Derivation of a triple mosaic adenovirus for cancer gene therapy.

Authors:  Yizhe Tang; Hongju Wu; Hideyo Ugai; Qiana L Matthews; David T Curiel
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

Review 6.  Engineering targeted viral vectors for gene therapy.

Authors:  Reinhard Waehler; Stephen J Russell; David T Curiel
Journal:  Nat Rev Genet       Date:  2007-07-03       Impact factor: 53.242

Review 7.  Gene Therapies for Cancer: Strategies, Challenges and Successes.

Authors:  Swadesh K Das; Mitchell E Menezes; Shilpa Bhatia; Xiang-Yang Wang; Luni Emdad; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2015-02       Impact factor: 6.384

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.